Revumenib Citrate
Revumenib citrate works by binding to a protein called menin. This prevents menin from interacting with a rearranged form of the KMT2A protein made by an abnormal KMT2A gene found in some leukemia cells. Blocking the interaction between menin and the rearranged KMT2A protein helps slow or stop the growth of leukemia cells. Revumenib citrate is a type of targeted therapy called a menin inhibitor.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Revumenib citrate is approved to treat adults and children aged 1 year and older with:
- acute leukemia that has an abnormal KMT2A gene and has come back or did not respond to previous treatment
Revumenib citrate is also being studied in the treatment of other types of cancer.
More About Revumenib Citrate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Revumenib Citrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.